Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 1/20 | 0.65 |
| ▸ | HTR1A | P08908 | 4/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | HTR7 | P34969 | 3/20 | 0.60 |
| ▸ | DRD2 | P14416 | 5/20 | 0.58 |
| ▸ | DRD4 | P21917 | 4/20 | 0.58 |
| ▸ | DRD3 | P35462 | 3/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3187864 | 0.90 | DRD2 (0.67) | HTR1AHTR7DRD2DRD4DRD3 | |
| Hydrochloric Acid SCHEMBL3207599 | 0.89 | DRD2 (0.65) | HTR1AHTR7DRD2DRD4DRD3 | |
| SCHEMBL3200957 | 0.85 | HTR1A (0.62) | CACNA1GHTR1AHTR7DRD2DRD3 | |
| SCHEMBL3187667 | 0.84 | CACNA1G (0.63) | CACNA1GHTR1AKDM4ELMNAHTR7 | |
| SCHEMBL3200095 | 0.84 | ADRA1B (0.56) | HTR1ALMNAHTR7DRD2DRD4 | |
| Hydrochloric Acid SCHEMBL3196046 | 0.83 | CACNA1G (0.62) | CACNA1GHTR1AKDM4ELMNAHTR7 | |
| SCHEMBL3210347 | 0.83 | DRD3 (0.54) | CACNA1GHTR1ADRD2DRD4DRD3 | |
| SCHEMBL11820063 | 0.82 | HTR1A (0.72) | CACNA1GHTR1AHTR7DRD2DRD4 | |
| SCHEMBL2113305 | 0.82 | HTR1A (0.76) | CACNA1GHTR1AKDM4ELMNAHTR7 | |
| SCHEMBL3196213 | 0.82 | DRD2 (0.57) | HTR1ADRD2DRD4DRD3ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029682-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | PIERRE FABRE MEDICAMENT (FR) | 2010-02-04 | — | — | US | claimed |
| WO-2011006794-A9 | 3-OXO-2, 3-DIHYDRO-1H-ISOINDOLE-4-CARBOXAMIDES AS PARP INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-05-05 | — | — | WO | disclosed |
| US-20100029682-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | PIERRE FABRE MEDICAMENT (FR) | 2010-02-04 | — | — | US | disclosed |
| EP-2057138-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | Pierre Fabre Medicament (FR) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008009741-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | PIERRE FABRE MEDICAMENT (FR) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029682-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | DRD3, CHRNA3, CHRM3 | CACNA1G 245/4885HTR1A 66/4885KDM4E 2673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.